Fund Evaluator:
Tema Oncology ETF (CANC)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$0.000
NAV (as of )
$0.00
Minimum Initial
0.75% F
Expense Ratio
$193 Mil
Assets
Open
Status
0.00%
12b-1 Fee
0.05%
TTM Yield
0.00%
Max Load
68%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 62.8% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 62.6% | Fidelity Advisor Biotechnology I (FBTIX) |
| 56.2% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 53.5% | Fidelity Select Biotechnology (FBIOX) |
| 49.5% | Fidelity Select Pharmaceuticals Port (FPHAX) |
Data as of 7/31/2026
-1.3% D
1-Mo Return
8.1% F
3-Mo Return
17.0% B
YTD Return
56.8% A
1-Yr Return
na
3-Yr Return
na
5-Yr Return
na
Category Risk Index
na
Total Risk Index
Fund Details
Fund Family
Tema ETFs
Inception Date
8/14/2023
Share Class Type
Equity Investment Style
Mid-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
No
Benchmark Index
S&P 500 (TR): 100%
Additional Fund Details
Tema Oncology ETF Overview
CANC Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| CANC Return (NAV) | -1.3% | 8.1% | 56.8% | na | na | na |
| CANC Grade | D | F | A | na | na | na |
| +/- Category | -0.9% | -2.5% | 22.9% | na | na | na |
| Health Avg | -0.4% | 10.7% | 33.9% | 10.7% | 5.0% | 9.3% |
| CANC Tax Cost Ratio | na | na | 0.0% | na | na | na |
CANC Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| CANC Return (NAV) | 17.0% | 42.8% | -4.5% | na | na | na | na | na | na | na | na |
| CANC Grade | B | A | F | na | na | na | na | na | na | na | na |
| +/- Category | 9.9% | 22.2% | -7.0% | na | na | na | na | na | na | na | na |
| Health Avg | 7.1% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | na |
| Total Risk Index: | na |
| Category Risk Index: | na |
| Category Risk Grade: | |
| Beta: | na |
| R-Squared: | na |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Mid-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.1% |
| Dividend Distribution: | Annually |
| Cap Gains Distribution: | Annually |
| Total Assets: | $193 Mil |
| Fund Total Assets: | $ 193 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 68% |
Management Team
| Number of Managers: 5 | |||
| Longest Tenure: 3.0 years | |||
| Average Tenure: 2.0 years | |||
| Managers (Year): Khodjamirian Yuri (2023), Pot Maurits (2023), Song David (2023), Hicks Andrew (2026), Duan Qiao (2026) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 59 |
| % in Top 10 Holdings: | 42.6% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 16.1% |
Portfolio Allocation |
|
| Domestic Stock: | 82.6% |
| Foreign Stock: | 16.1% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 1.3% |
Purchase Information
| Fund Family: | Tema ETFs |
| Phone Number: | 888-744-1377 |
| Website: | www.tema.co |
| Status: | Open |
| Inception Date: | August 14, 2023 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | 0.00% |
Expenses and Fees | |
| Expense Ratio (%): | 0.75% ( Rating : Above Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Tema Oncology ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.